San Francisco startup Framework Therapeutics can be working on an oral, at the time-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Road’s expectations in June each time a mid-stage study showed normal weight loss of all-around six% and it ideas to get started on A different mid-phase trial in direction of the top of this year—th